DaVita Counts $70 Million Offset Math for 2027 Reimpression

DaVita expects roughly $70 million in reimbursement pressure in 2027, and Chief Financial Officer Joel Ackerman says stronger dialysis volume growth and pharmaceutical cost savings should absorb most of it. The figure came on top of approximately $40 million the company absorbed this year, according to the conference operator hosting his remarks.

The pressure stems from a decline in commercial insurance mix tied to the expiration of enhanced premium tax credits. Ackerman said at the investor conference that patients who leave the exchanges mostly move to Medicare or Medicare Advantage, though some find other commercial coverage. DaVita is watching how many retain exchange coverage or obtain employer-sponsored insurance.

The company's existing patients, he noted, have kept exchange coverage at better-than-expected rates even after losing the enhanced credits. The harder question is what arrives next: new patients are entering dialysis with a lower commercial insurance mix, which delays the hit to DaVita relative to some competitors but does not remove it.

What does the Medicare payment picture actually look like?

DaVita estimates the 2027 Medicare dialysis payment increase for large dialysis organizations will land at 1.5% to 2% for the full year — not the headline 3.5% cited for the first quarter. The gap reflects uncertainty around payments tied to drugs leaving the transitional drug add-on payment adjustment, or TDAPA.

Ackerman said changes in average sales price and potentially utilization of DefenCath will affect rates after the first quarter. Because DaVita has no exposure to that product, a decline in associated reimbursement would cut revenue without cutting costs. That asymmetry deserves attention; a 3.5% headline and a 2% reality are different businesses.

The mitigation levers are concrete: contracting, generic conversion, changes in drug mix and dosing modifications. Ackerman stressed that prescribing decisions remain entirely physician-driven.

"We think the cost savings opportunities on pharma are bigger than normal in 2027," he said. Bigger than normal, however, is not yet a number, and the CFO did not quantify the gap.

Where does volume growth stand?

Treatment volume growth should turn positive this year and improve in 2027, Ackerman said, while cautioning that October results are too early to read for fourth-quarter trends.

The calendar arithmetic:

• Approximately 50 basis points of improvement in the 2027 volume growth comparison from calendar effects;
• An estimated 25-basis-point nonrecurring benefit this year from Fresenius clinic closures, which reverses out;
• A net tailwind of about 25 basis points before other factors.

DaVita is also accelerating a nationwide rollout of expanded hemodialysis dialyzers after a pilot involving about 10,000 patients. Ackerman credited physician enthusiasm, operational readiness and available supply. He did not expect a financial impact until the second half of 2028, citing the timing of mortality differences observed in the CONVINCE study — with the caveat that real-world results may differ from clinical trials. The company targets a return to at least 2% volume growth by 2029.

What about technology spend and the other businesses?

Technology spending has grown by more than 20% annually for roughly four years and remains a significant cost headwind. Ackerman expects spending to keep rising next year, at a slower rate. DaVita has increased artificial intelligence investment this year and has not yet seen returns from it — a promise of future payoff, with no evidence offered yet.

The international business is performing as expected. The IKC business is having a strong year and should contribute about 2% to operating income growth, against the 1% the company usually cites. A new Humana relationship covering chronic kidney disease patients will create an economic headwind in the second half of this year and the first half of next, because DaVita generally incurs costs before it generates revenue.

On capital allocation, Ackerman said DaVita intends to invest in growth and innovation, hold leverage within its 3 to 3.5 times target range and preserve liquidity. When suitable investments are absent, the company generally plans to direct free cash flow to share repurchases.

DaVita, founded in 1994 as Total Renal Care and renamed in 2000, operates outpatient dialysis centers for patients with chronic kidney failure, alongside home dialysis programs, hospital dialysis services and care coordination, primarily in the United States with international operations.

The offsets are plausible; the arithmetic that proves them arrives in 2027.